Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is a lack of evidence whether adipose-produced MCP-1 contributes to breast cancer.
|
31837540 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that CCL2 secreted by TAMs activates PI3K/Akt/mTOR signaling and promotes an endocrine resistance feedback loop in the TME, suggesting that CCL2 and TAMs may be novel therapeutic targets for patients with endocrine-resistant breast cancer.
|
31710162 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, IL-6 promoted the proliferation of normal cells and CCL2 induced the M2-like polarization of macrophages, which might create an immunosuppressive microenvironment during the initiation and/or development of breast cancer.
|
30671946 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer.
|
30368555 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Media conditioned by the MDA-MB-231 cells promoted the expansion, chemotactic migration, and immunosuppressive activity of Tregs, and these effects were attenuated in a dose-dependent manner by ZA treatment, and the attenuation was due to reduced expression of selected breast cancer cell factors (CCL2, CCL5, and IDO).
|
30808421 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While the importance of CCL2/CCR2 signaling in macrophages during cancer progression is well documented, we recently showed that CCL2-mediated breast cancer progression depends on CCR2 expression in carcinoma cells.
|
31208996 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CCL2/CCR2 chemokine pathway is best known for regulating breast cancer progression through macrophage-dependent mechanisms.
|
30446625 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CCR2 overexpression increased SUM225 breast cancer survival and invasion associated with accumulation of CCL2 expressing fibroblasts.
|
29133591 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-C Chemokine Ligand 2 (CCL2) Recruits Macrophage-Membrane-Camouflaged Hollow Bismuth Selenide Nanoparticles To Facilitate Photothermal Sensitivity and Inhibit Lung Metastasis of Breast Cancer.
|
30141614 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentration of CCL2 in BC increases with advancing tumor stage, while a median level of CCR2 decreases with advancing stage.
|
30151375 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, CCL2-CCR2 axis may represent as a novel therapeutic target eagerly needed for hormone-dependent breast cancer.
|
29934505 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings collectively indicate that TGF-β regulates CCL2 and CCL5 expression in a stage-dependent manner during BCa progression, which in turn, determines Th1-Th2 balance within the tumor microenvironment.
|
29107385 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effects of continuous delivery of human CCL2-neutralizing antibodies on breast cancer progression.
|
28734227 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.
|
28475599 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings revealed that MCP-1-induced EMT and migration are mediated by the ERK/GSK-3β/Snail pathway, and identified a potential novel target for therapeutic intervention in breast cancer.
|
26996066 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women with high mammographic density.
|
28077158 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to better understand how tumors engage distal sites and activate a pro-inflammatory response we utilized syngeneic breast cancers as a model and showed that soluble factors from the neoplastic epithelium activate the expression of the monocyte chemoattractive protein (MCP) chemokines of the mouse 11C cluster that include Ccl1, Ccl2, Ccl7, Ccl8, Ccl11 and Ccl12.
|
28041977 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The TCGA data base was queried for relationship between CCL2 expression and relapse free survival of breast cancer patients and compared to subsets of breast cancer patients.
|
28143493 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest a tumor-promoting role for CCL2 acting through CCR2 on the tumor microenvironment and support the targeting of this chemokine/receptor pair in breast cancer.
|
27820834 |
2016 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
All three variables viz.NF-κB, CCL2 and CD68 showed significant (p<0.05 or p<0.01 or p<0.001) respectively associations with both clinicopathological (except CD68 with stage) and hormone receptors (ER, PR and Her2/neu) and their co-expressions indicating these as predictors of breast cancer.
|
26950462 |
2016 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings shed new light on the mechanisms underlying the progression of ER(+) breast cancer and indicate the potential of novel therapies targeting CCL2 and CCL5 pathways.
|
25901081 |
2015 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individuals carrying the MCP1 -2518GG genotype had a two fold risk for breast cancer (OR=2.06, 95%CI, 1.06-3.98; p=0.03).
|
26514518 |
2015 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identified the impact of TNF-α and IL-1β on the inflammatory phenotype of CAFs and MSCs by determining the expression of inflammatory chemokines that are well-characterized as pro-tumorigenic in breast cancer: CCL2 (MCP-1), CXCL8 (IL-8) and CCL5 (RANTES).
|
25928089 |
2015 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The chemokine CCL2 is overexpressed in breast cancer, correlating with poor patient prognosis.
|
25744294 |
2015 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study also indicates that targeting breast cancer cell p38β and its product MCP-1 may be a viable approach to treat or prevent bone destruction in patients with bone-metastatic breast cancer.
|
25066918 |
2014 |